These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 26758586)

  • 21. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
    Lara PN; Koczywas M; Quinn DI; Lenz HJ; Davies AM; Lau DH; Gumerlock PH; Longmate J; Doroshow JH; Schenkein D; Kashala O; Gandara DR
    J Thorac Oncol; 2006 Feb; 1(2):126-34. PubMed ID: 17409841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer.
    Lilenbaum R; Rubin M; Samuel J; Boros L; Chidiac T; Seigel L; Dowlati A; Graham P; Beaumont J; Du H
    J Thorac Oncol; 2007 Apr; 2(4):306-11. PubMed ID: 17409802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis.
    Pujol JL; Paul S; Chouaki N; Peterson P; Moore P; Berry DA; Salzberg M
    J Thorac Oncol; 2007 May; 2(5):397-401. PubMed ID: 17473654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer.
    Jones S; Thompson D; Barton J; Patton J; Shipley D; Greco FA; Spigel D; Infante J; Burris HA
    Clin Lung Cancer; 2008 May; 9(3):154-9. PubMed ID: 18621625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II trial of biweekly chemotherapy with docetaxel and cisplatin in high-risk patients with unresectable non-small cell lung cancer.
    Kim MJ; Kim SH; Kang JH; Kim HG; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim MG; Choi JY; Lee GW
    Chemotherapy; 2013; 59(3):159-66. PubMed ID: 24107481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.
    Yoshimura N; Kudoh S; Kimura T; Mitsuoka S; Kyoh S; Tochino Y; Asai K; Kodama T; Ichimaru Y; Yana T; Hirata K
    J Thorac Oncol; 2009 Mar; 4(3):371-5. PubMed ID: 19155998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer.
    Kim HJ; Kim TG; Lee HJ; Kim JH; Lim BH; Seo JW; Kang EM; Lee BU; Ahn YM; Roh YH; Nam SH; Kim BS
    Lung Cancer; 2010 May; 68(2):248-52. PubMed ID: 19647333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
    Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
    Kim ES; Hirsh V; Mok T; Socinski MA; Gervais R; Wu YL; Li LY; Watkins CL; Sellers MV; Lowe ES; Sun Y; Liao ML; Osterlind K; Reck M; Armour AA; Shepherd FA; Lippman SM; Douillard JY
    Lancet; 2008 Nov; 372(9652):1809-18. PubMed ID: 19027483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
    Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
    Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retrospective analysis of safety and efficacy of low-dose docetaxel 60 mg/m2 in advanced non-small cell lung cancer patients previously treated with platinum-based chemotherapy.
    Nakamura Y; Kunitoh H; Kubota K; Sekine I; Yamamoto N; Tamura T; Kodama T; Saijo N
    Am J Clin Oncol; 2003 Oct; 26(5):459-64. PubMed ID: 14528070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis.
    Zhong A; Xiong X; Shi M; Xu H
    Drug Des Devel Ther; 2015; 9():3685-93. PubMed ID: 26229433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy.
    Krzakowski M; Ramlau R; Jassem J; Szczesna A; Zatloukal P; Von Pawel J; Sun X; Bennouna J; Santoro A; Biesma B; Delgado FM; Salhi Y; Vaissiere N; Hansen O; Tan EH; Quoix E; Garrido P; Douillard JY
    J Clin Oncol; 2010 May; 28(13):2167-73. PubMed ID: 20351334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
    Garon EB; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Gorbunova V; Kowalyszyn RD; Pikiel J; Czyzewicz G; Orlov SV; Lewanski CR; Thomas M; Bidoli P; Dakhil S; Gans S; Kim JH; Grigorescu A; Karaseva N; Reck M; Cappuzzo F; Alexandris E; Sashegyi A; Yurasov S; Pérol M
    Lancet; 2014 Aug; 384(9944):665-73. PubMed ID: 24933332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II randomized trial of tri-weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer.
    Lai CL; Tsai CM; Chiu CH; Wang GS; Su WJ; Chen YM; Perng RP
    Jpn J Clin Oncol; 2005 Dec; 35(12):700-6. PubMed ID: 16303792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).
    Ardizzoni A; Tiseo M
    J Chemother; 2004 Nov; 16 Suppl 4():104-7. PubMed ID: 15688623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer.
    Feliu J; Martín G; Castro J; Sundlov A; Rodriguez-Jaráiz A; Casado E; Lomas M; Madroñal C; Galán A; Belda C; Gonzalez-Barón M
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):527-31. PubMed ID: 16555090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).
    Kawaguchi T; Ando M; Asami K; Okano Y; Fukuda M; Nakagawa H; Ibata H; Kozuki T; Endo T; Tamura A; Kamimura M; Sakamoto K; Yoshimi M; Soejima Y; Tomizawa Y; Isa S; Takada M; Saka H; Kubo A
    J Clin Oncol; 2014 Jun; 32(18):1902-8. PubMed ID: 24841974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest Oncology Group (S0027).
    Hesketh PJ; Chansky K; Lau DH; Doroshow JH; Moinpour CM; Chapman RA; Goodwin JW; Gross HM; Crowley JJ; Gandara DR
    J Thorac Oncol; 2006 Jul; 1(6):537-44. PubMed ID: 17409914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
    Jiang J; Huang L; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
    Acta Oncol; 2011 May; 50(4):582-8. PubMed ID: 21190510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.